Eiger BioPharmaceuticals Inc (EIGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
66
About the Report
About the Report
Summary
Eiger BioPharmaceuticals Inc (Eiger), formerly Celladon Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercializationof novel drugs for the treatment of orphan diseases. The company provides pipeline products such as Lonafarnib and Lambda, which are in Phase 2 trials used for the treatment of hepatitis delta virusinfection; Exendin 9-39, a phase 2 program for post-bariatric hypoglycemia;Ubenimex, a phase 2 program for lymphedema and pulmonary arterial hypertension. It offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company offers post bariatric hypogiycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.
Eiger BioPharmaceuticals Inc (EIGR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Eiger BioPharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12
Venture Financing 13
Eiger BioPharma Raises USD3 Million in Venture Financing 13
Celladon Raises USD3 Million in Venture Financing 14
Eiger BioPharma Raises USD6 Million in Venture Financing 15
Eiger Biopharma Raises USD 1 Million In Third Tranche Of Series A Financing 16
Partnerships 17
Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17
Merger 18
Eiger BioPharma Merges with Celladon 18
Licensing Agreements 20
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21
Eiger BioPharma Enters into Licensing Agreement with Stanford University 22
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23
Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25
Equity Offering 26
Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26
Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28
Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30
Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32
Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33
Asset Transactions 35
Eiger BioPharma Sells Mydicar to Theragene Pharma 35
Eiger BioPharmaceuticals Inc-Key Competitors 36
Eiger BioPharmaceuticals Inc-Key Employees 37
Eiger BioPharmaceuticals Inc-Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 10, 2018: Eiger Biopharmaceuticals announces second quarter 2018 financial results 39
May 11, 2018: Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results 40
Mar 12, 2018: Eiger BioPharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 41
Nov 09, 2017: Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results 42
Aug 14, 2017: Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results 44
May 12, 2017: Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results 45
Mar 23, 2017: Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 47
Corporate Communications 49
Jan 08, 2018: Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors 49
Jan 03, 2018: Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer 50
Sep 18, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors 51
Jun 14, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors 52
Apr 18, 2017: Eiger BioPharmaceuticals appoints new lead for development of PBH treatment 53
Product News 54
04/18/2017: Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia 54
Product Approvals 55
Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 55
Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 56
May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection -LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling 57
Clinical Trials 58
Aug 14, 2018: Eiger BioPharmaceuticals completes enrolment in Prevent trial 58
Mar 26, 2018: Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia 59
Oct 23, 2017: Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the American Association for the Study of Liver Diseases Meeting 60
Oct 02, 2017: Eiger Announces Presentation on Lambda at the American Association for the Study of Liver Diseases Meeting 61
Jul 24, 2017: Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 62
Jun 12, 2017: Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego 63
Jun 06, 2017: Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
List of Figure
List of Figures
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12
Eiger BioPharma Raises USD3 Million in Venture Financing 13
Celladon Raises USD3 Million in Venture Financing 14
Eiger BioPharma Raises USD6 Million in Venture Financing 15
Eiger Biopharma Raises USD 1 Million In Third Tranche Of Series A Financing 16
Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17
Eiger BioPharma Merges with Celladon 18
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21
Eiger BioPharma Enters into Licensing Agreement with Stanford University 22
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23
Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25
Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26
Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28
Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30
Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32
Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33
Eiger BioPharma Sells Mydicar to Theragene Pharma 35
Eiger BioPharmaceuticals Inc, Key Competitors 36
Eiger BioPharmaceuticals Inc, Key Employees 37
Eiger BioPharmaceuticals Inc, Subsidiaries 38
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.